contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


moberg-pharma-ytterligare-en-terbinafin-leverantor-godkand

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Moberg Pharma is a Swedish pharmaceutical company with a focus on commercialization of proprietary drugs based on proven substances. The company works primarily in nail fungus, where Moberg Pharma is developing a topical treatment. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among other places. The company's headquarters are located in Bromma.

After the USA disappointment, the strategy is now the EU. The market has punished. Jan-Mar Oct-Dec Jul-Sep Apr-Jun Jan-Mar  2025 2024 2024 2024 2024  values in thousands SEK  Net revenue 3,869 1,027 3,855 4,109 820  Cost of goods sold -1,304 -1,165 -615 -1,388 -328  Gross profit 2,565 -138 3,240 2,721 492 OPEX is between 5-7 MSEK. Cash is 269 MSEK. MCAP 394 MSEK. Terclara is #1 in Sweden and the total market has also grown. This means there is hidden demand that current products have not met. Summer months are the best for sales. This should turn profitable.

The conference call recording has now been published on Moberg’s website: Sidan kunde inte hittas | Moberg Pharma In my opinion, it didn’t provide much additional information:  -They are not publishing patient numbers or percentages because they want to “protect” the blinded data (I interpret this to mean that preliminary information about the results shouldn’t influence the results themselves or the analysis of the results).  -The data came as a surprise to the company as well, apparently in connection with some other discussion.  -The data is “disappointing” according to the CEO, but even they don’t have more detailed data yet (e.g., information on mycological efficacy), and no conclusions regarding the US launch can be made yet.  -It does not affect the launch in the EU region. In the EU, getting new terbinafine suppliers approved has a greater impact, and new marketing authorizations in the EU cannot (??) be applied for until there are new suppliers.  -It likely won’t affect launches in Israel, the UK, or Canada either. In Japan, a separate study is apparently needed regardless of the current study. If I recall correctly, the Japanese partner ended the collaboration even before the EU marketing authorizations.  -Market share is now 40% in Sweden (I interpret this as referring to topical treatments) and it is the market leader. Based on this, I would assume that the US study won’t have much of an impact on those countries where Terclara will be sold over-the-counter.  -The launch in EU countries might be delayed until 2026. I thought the explanation for this was very strange: that it needs to be brought to market early in the year when demand is at its peak. I don’t understand the logic here. For example, regarding Southern Europe, it probably doesn’t matter much if the product is released as late as autumn. But increasing sales in Europe seems slow. There is also a delay of about 6 months from pharmacies (they take on new products for sale 2-3 times a year). Perhaps the share price reaction is a bit of an overreaction (-61%), but on the other hand, the uncertainty will continue until December when the final data is published. Even if marketing authorization is not obtained for the US, Terclara will be sold at least in the EU region.

A rather vague press release since it doesn’t disclose the number of patients for whom data has been obtained, nor what that “clinical cure rate” was versus what was expected. The data is still blinded (at least that’s how I understand the release), so a fairly essential piece of information would be at least what portion of the study population this data covers. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). I wonder where the recording or transcript of the conference call mentioned in the release might be found?

Moberg Pharma              Sidan kunde inte hittas    Page not found                             A major blow: according to preliminary data, the drug’s efficacy is weaker than expected. The press release still leaves some things open to speculation, but the market has already drawn its conclusions.

Interim Report May 7th                  Moberg Pharma              Sidan kunde inte hittas    Page not found                             Some sales are already happening in Sweden. Marketing authorizations have now been received in all 13 EU countries that participated in the licensing process, and Terclara is coming to market over-the-counter (OTC) in countries like Italy and the Netherlands, though it requires a prescription in Finland, for example. This comment from the CEO seems quite positive: “A majority of ~1,400 Swedish pharmacies now have MOB-015 available on the shelf under the brand name Terclara® and interest is exceeding the chains’ forecasts. The pharmacy chains are increasing their orders after consumer marketing began around the end of March due to the fact that the product occasionally has sold out at several of the pharmacy chains” Sales in other European countries are starting off sluggishly. Based on previous comments, I thought sales would have started faster at least in the other Nordic countries, but it seems we might have to wait for a new terbinafine supplier before sales can expand. An application for a new terbinafine supplier was submitted in April, and according to the press release, the authorization should be obtained before the end of the year. The cash position looks poor at a quick glance, but hopefully, the exercise of warrants will fix the situation. The stock has been on a strong upward trend lately, and at these prices, the warrants expiring in June are set to bring a lot of money into the coffers. This is, of course, entirely dependent on the stock price and how many warrants are ultimately exercised. Does anyone here have any insight or previous experience regarding what is likely to happen with the warrants? Will the stock price drop closer to the subscription price, and are the warrants a risky investment in that sense?

Today’s update from Redeye                   redeye.se              Moberg Pharma Q4’2023: Lots of progress in a short time    Redeye sees the end-of-year report as results as uneventful. More important were the indications of a good start to the Swedish launch, the conclusion of the enrollment to the Phase 3 study, and prog                             Edit, adding yesterday’s CEO interview as well, requires free registration on Redeye                   redeye.se              Moberg Pharma: Intervju med vd Anna Ljung    Redeye har intervjuat Anna Ljung, vd för Moberg Pharma. Vi diskuterade utvecklingen i Q4, Svenska lanseringen och tidslinjen i EU och USA.

A press release was issued yesterday stating that sales have (finally) started in Sweden and it’s apparently available in most pharmacies now. Sidan kunde inte hittas | Moberg Pharma. It is also available for order from online pharmacies without a prescription, and the price seems reasonable for both the consumer and the seller, i.e., slightly under 40e/package: https://www.kronansapotek.se/Terclara/p/042620/ Based on published studies, the product’s efficacy should be quite good compared to other nail fungus treatments and is comparable to oral terbinafine. The temporary whitening of the nail as nail permeability improves (moisture content increases) shouldn’t be a long-term problem if the mycological efficacy is truly good. The product’s efficacy is based specifically on this improvement in nail permeability. Topical terbinafine alone without excipients has been tested in randomized trials before, and the efficacy was very poor. More will be known about the efficacy and potentially fewer aesthetic drawbacks with reduced dosing after the currently ongoing study in early 2025. It was also commented above that nail fungus is only an aesthetic issue. This is certainly true for mild cases, but as it progresses, the fungus does cause pain as the nail thickens and changes shape, as well as predisposing to other infections and nail detachment. Personally, I consider the presented sales potential to be entirely possible if the efficacy is truly as good as the company promises and the product becomes widely available as an over-the-counter (OTC) preparation. In that case, it is possible that Terclara will become the primary treatment for mild and moderate nail fungus worldwide.

Moberg Pharma

STOCKHOLM, den 13 mars 2026. Moberg Pharma AB (OMX: MOB) meddelar idag att en ytterligare leverantör av terbinafin har godkänts för MOB-015, bolagets läkemedel mot nagelsvamp. Den regulatoriska...

<div class="abstract">STOCKHOLM, den 13 mars 2026. Moberg Pharma AB (OMX: MOB) meddelar idag att en ytterligare leverantör av terbinafin har godkänts för MOB-015, bolagets läkemedel mot nagelsvamp. Den regulatoriska godkännandeprocessen som inleddes i april 2024 är därmed avslutad med positivt resultat.</div>Moberg Pharma har därmed två alternativa terbinafin-leverantörer säkrade, där varje leverantör har kapacitet att täcka bolagets globala terbinafin-behov. Detta är i linje med bolagets generella kvalitetsarbete och säkerställer en stabil tillgång till den aktiva substansen. För ytterligare information kontakta: Anna Ljung, VD, telefon: +46&nbsp;8&nbsp;522&nbsp;307 01, e-post: <a href="mailto:anna.ljung@mobergpharma.se">anna.ljung@mobergpharma.se</a>.Om denna information Denna information lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 13 mars 2026 kl. 15.00 CET.Om Moberg Pharma, <a href="http://www.mobergpharma.se">www.mobergpharma.se</a> Moberg Pharma AB (publ) är ett svenskt läkemedelsbolag med fokus på kommersialisering av egenutvecklade läkemedel baserade på beprövade substanser. Bolagets läkemedel MOB-015 är en ny utvärtes behandling av nagelsvamp, med marknadsgodkännande i 13 EU länder. MOB-015 säljs i Sverige och Norge under varumärket Terclara® och finns på samtliga apotekskedjor. Kliniska fas 3-studier av fler än 800 patienter för MOB-015 indikerar att produkten har potential att bli den framtida marknadsledaren inom nagelsvamp. Moberg Pharma har avtal med kommersiella partners på plats i bland annat Europa och Kanada. Moberg Pharma har huvudkontor i Stockholm och bolagets aktie är noterad under Small Cap på Nasdaq Stockholm (OMX: MOB).<div></div>